Oxford Textbook of Clinical Nephrology Volume 3

Capa
Alex M. Davison
Oxford University Press, 2005 - 2749 páginas
Unequivocally the most relevant and important European textbook of clinical nephrology. This is the most authoritative, well written and comprehensive textbook of clinical nephrology combining the clinical aspects of renal disease important for the daily clinical practice whilst giving extensive information about the underlying basic science and current evidence available. This new edition highlights the numerous changes in clinical management that have arisen as a result of recently concluded clinical trials and there are now specific formal guidelines for optimal treatment of patients. Each section of the textbook has been critically and comprehensively edited under the auspices of one of the leading experts in the field. This text for this third edition has been ruthlessly edited, balanced, updated and pitched at the adult nephrologist. The emphasis throughout is on marrying advances in scientific research with clinical management. Where possible treatment algorithms are included to aid patient care. By comparison with other texts, Oxford Textbook of Clinical Nephrology has more than average coverage of paediatric issues. For this edition there has been increased focus on age and renal disease, nephrology as practised in countries of different stages of socio-economic development, evidenced-based nephrology, clinical outcomes, clinical audit and moral and ethical issues. Richly illustrated throughout in full colour this is truly a modern and attractive edition with comprehensive coverage of everything that has to do with clinical nephrology written by the worlds experts in the respective fields.
 

Opinião das pessoas - Escrever uma crítica

Não foram encontradas quaisquer críticas nos locais habituais.

Páginas seleccionadas

Índice

The patient with Preface to the third edition
xvii
basis of ultrafiltration 347 Contributors
xxiii
11 3 13 Dermatological disorders
1879
Section 12 The patient on dialysis
1899
Charles van Ypersele recipient
2073
B Other inherited metabolic storage disorders
2351
renal function 2193 16 5 Inherited metabolic diseases
2367
Ian A Greer involvement
2407
Wolfgang Rascher and Wolfgang H Rosch 18 5 Tumours of the prostate
2567
Volume
3
Direitos de autor

Outras edições - Ver tudo

Palavras e frases frequentes

Passagens conhecidas

Página 1789 - Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342: 145-153.
Página 1766 - Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Página 1682 - The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878.
Página 1678 - Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857.
Página 1766 - Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S.
Página 2058 - Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med.
Página 1713 - Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
Página 2002 - Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities, Am J Kidney Dis 15(5):458-482, 1990.
Página 1681 - Maschio G, Alberti D, Janin G, et al: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N EnglJ Med 1996;334:939-945.
Página 1715 - Lewis EJ, Hunsicker LG, Clarke WR et al.: Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.

Referências a este livro

Informação bibliográfica